Gastro
01 Jan 2013
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
Ulcerative Colitis Clinical Trial
Research and Trials
01 Jan 2013
Study In People With Type 2 Diabetes
Primary Outcomes: Improvement in glucose control over a 16 week period. Secondary Outcomes: Cholesterol, additional glycemic endpoints, safety endpoints. Official Title A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once A Day)…
Research and Trials
01 Jan 2013
Impact of Tight Glycaemic Control in Acute Myocardial Infarction
Primary Outcomes: Difference in the change in wall motion score index between admission, day 3-5 and after 3 months in the two treatment arms. Secondary Outcomes: Changes in inflammatory/endothelial markers and myocardial perfusion from admission, day 3-5 and after 3 months between the two treatment arms. Researchers will randomise…
Cancer
01 Jan 2013
CIBO-P for pts with poor prognostic refractory or multiple disease recurrent aggressive NHL
Aim: To assess the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive NHL, to evaluate the long-term results, and identify prognostic factors in the study cohort. Conclusions: In the current study, CIBO-P was a novel, highly active, and safe combination therapy for patients…
Cancer
01 Jan 2013
Factors Affecting HD pts treated with IEGV and HDT with stem cell rescue
Aim: To identify prognostic factors in patients with relapsing/refractory Hodgkin’s Disease treated with IGEV Chemotherapy and High Dose Consolidation Therapy. Conclusions: Based on this analysis, a prognostic model for IGEV-treated patients with refractory/relapsed HD can be constructed using the above factors. Official Title Factors Affecting Outcome of Patients with Refractory/Relapsed…
Cancer
01 Jan 2013
R-GIFOX for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma
Aim: To evaluate the clinical activity, toxicity and mobilizing capacity of a new short-course (bi-weekly), dose intensive, cytoreductive/mobilizing salvage regimen (R-GIFOX) combining the cross-synergistic agents Gemcitabine (G), Ifosfamide (Ifo), Oxaliplatin (Ox) and Rituximab (R) in patients with relapsed and refractory CD20+ NHL. Conclusions: R-GIFOX was feasible, tolerable, effective…
Blood
01 Jan 2013
Comparison between Cy then G-CSF and IVE Plus G-CSF in Haematological Malignancies
Aim: To retrospectively compare the PBPC yields of harvests after IVE with those of standard Cy/G-CSF priming. Conclusions: Priming with IVE yields higher PBPC numbers than cyclophosphamide, patients requiring fewer pheresis, therefore reducing the cost. Official Title A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and…
Cancer
01 Jan 2013
Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI
Aim: To explore a more effective treatment for newly-diagnosed localized nasal NK/T-cell lymphoma, we conducted a multicenter phase I/II study of concurrent chemoradiotherapy. Conclusions: Researchers concluded results suggest that concurrent chemoradiotherapy using MDR- non-related agents and ETP is a promising treatment strategy for localized nasal NK/T-cell…
Cancer
01 Jan 2013
An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation
Aim: To assess efficacy and toxicity of 2 and 3 drug salvage regimens. Conclusions: Researchers concluded that both VGF and F-GIV can be safely administered on an outpatient basis and show activity against advanced lymphoma Official Title Conditions Study Type Phase II Study Design Patients were stratified into:…
